Shares fell about 41% in a month after a $500 million raise. Investors want details on the new SUNRISE oral trial, which follows phase 2 weight loss of up to 12.2% in 13 weeks.
Recap by typeshit. Full story at 24/7 Wall St..
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
The Atlanta Journal-Constitution looks at how an unapproved weight loss drug is being sold through an underground market across Georgia.
The AJC found clinics in Georgia promoting and dispensing copies of retatrutide, a drug that has not been approved. Tap through for how they are getting away with it.
Loading…